Lunai Bioworks Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LNAI research report →
Price Chart
About the company
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
- CEO
- David H. Weinstein
- IPO
- 2025
- Employees
- 29
- HQ
- Los Angeles, CA, US
Get TickerSpark's AI analysis on LNAI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $9.97M
- P/E
- -0.04
- PEG
- 0.00
- P/S
- 476.29
- P/B
- -0.72
- EV/EBITDA
- -0.06
- Div Yield
- 0.00%
- Gross Margin
- -360.71%
- Op Margin
- -46991.97%
- Net Margin
- -612568.11%
- ROE
- 892.52%
- ROIC
- 120.87%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-129,094+0.0%
- Op Income
- $-18,546,573
- Net Income
- $-178,007,489-101.3%
- EPS
- $-86.24-18.5%
- OCF Growth
- +28.2%
- FCF Growth
- +28.7%
- 52W High
- $21.20
- 52W Low
- $1.21
- 50D MA
- $2.73
- 200D MA
- $4.65
- Beta
- 0.32
- RSI (14)
- 41
- Avg Volume
- 996.20K
No earnings-call transcripts are available for LNAI yet.
- Free Float
- 55.6%
- Shares Outstanding
- 4.53M
- Float Shares
- 2.52M
Held by 4 ETFs
Biggest fund positions in LNAI by dollar value.
Our LNAI coverage
Recent articles, reports, and earnings notes.
No research on LNAI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate LNAI report →Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
prnewswire.com · Aug 4
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
prnewswire.com · Aug 4
LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS
prnewswire.com · Jun 17
Lunai Bioworks (LNAI) Stock Is Trending Overnight — Here's Why It Spiked Nearly 81% In After-Hours Session
feeds.benzinga.com · Jun 17
Lunai Bioworks and BrainStorm Therapeutics Launch Foundation-Funded Parkinson's and Rare Epilepsy AI Discovery Collaboration
prnewswire.com · May 28
Federal Judge Orders Expedited Discovery to Identify 'John Doe' Defendants 'Naked' Short-Sellers of Lunai Common Stock
prnewswire.com · May 22
LUNAI BIOWORKS, INC. ANNOUNCES REVERSE STOCK SPLIT
prnewswire.com · May 20
Dickinson Wright and Fox Rothschild Join Forces to File Lawsuit Against ‘John Doe' ‘Naked' Short-Sellers of Lunai Common Stock
globenewswire.com · May 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.